Short- and Long-Acting Oral Quinidine Preparations

Woo, Elaine; Greenblatt, David J.
March 1978
Angiology;Mar1978, Vol. 29 Issue 3, p243
Academic Journal
Discusses the clinical implications of pharmacokinetic differences of short- and long-acting oral quinidine preparations. Absorption properties of oral quinidine gluconate; Use of quinidine to suppress ventricular arrhythmias; Maintenance dose and dosing interval.


Related Articles

  • QUINIDINE.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1018 

    The article presents a guide for nurses about quinidine, an antiarrhythmic agent. It is used in the management of a variety of atrial and ventricular arrhythmias, including atrial premature contractions. Its pharmacokinetics, contraindications, side effects and interactions are cited. Nursing...

  • Clinical Pharmacology and Pharmacokinetics of Pirmenol. Reiter, Michael J. // Angiology;Mar1988 Part 2, Vol. 39, p293 

    Pirmenol hydrochloride is a promising antiarrythmic agent with quinidine-like (Class Ia) properties presently undergoing evaluation. It's clinical pharmacology and pharmacokinetics are reviewed. The author outlines the effects of pirmenol on the sinus node, atrial tissue, A-V node, and...

  • Impact of Stereoselectivity on the Pharmacokinetics and Pharmacodynamics of Antiarrhythmic Drugs. Mehvar, R.; Brocks, D.R.; Vakily, M. // Clinical Pharmacokinetics;2002, Vol. 41 Issue 8, p533 

    Many antiarrhythmic drugs introduced into the market during the past three decades have a chiral centre in their structure and are marketed as racemates. Most of these agents, including disopyramide, encainide, flecainide, mexiletine, propafenone and tocainide, belong to class I antiarrhythmics,...

  • Class 1-A (Quinidine, Procainamide, Disopyramide).  // Cardiovascular Pharmacology Manual;2008, p40 

    The article presents information about several class 1-A anti-medications, they include quinidine, procainamide and disopyramide. One of their uses is for the management of different kinds of atrial and ventricular arrhythmia. Their adverse effects include hypotension, anorexia, blurred vision...

  • THE EFFECT OF QUINIDINE ON EXPERIMENTAL COMPETITIVE CARDIAC PACING. Rothfeld, Edwin L.; Zucker, I. Richard; Lotti, Luigi; Parsonnet, Victor; Bernstein, Arthur // Angiology;Feb1967, Vol. 18 Issue 2, p122 

    No ventricular arrhythmias occurred during competitive pacing between the sinus node and an artificial pacemaker in 20 normal dogs. After intravenous quinidine serious ventricular arrhythmias triggered by pacemaker stimuli falling in the vulnerable period of sinus beats were noted in 14 of the...

  • Drugs for atrial fibrillation. Lip, Gregory Y.H.; Watson, Robert D.S. // BMJ: British Medical Journal (International Edition);12/16/95, Vol. 311 Issue 7020, p1631 

    Provides information on antiarrhythmic drugs for the control of arrhythmia in patients who are symptomatic, have malignant arrhythmias or are hemodynamically compromised. Digoxin; Verapamil and diltiazem; Class I and Class III antirrhythmic drugs.

  • QUINIDINE.  // Davis's Drug Guide for Nurses, 9th edition;2005, p906 

    Deals with the antiarrhythmic agent quinidine. Indications; Pharmacokinetics; Adverse reactions and side effects.

  • Quinidine for Pharmacological Cardioversion of Long-lasting Atrial Fibrillation. Baroni, Matteo; Kheir, Antoine; Manfredi, Margherita; Pattarino, Francesco; Doni, Flavio // JAFIB: Journal of Atrial Fibrillation;Jul2011, Vol. 2 Issue 6, p1 

    Background: In the daily clinical practice, patients with atrial fibrillation (AF) lasting more than 48h (or not datable at all) are not uncommon. In long-lasting AF changes in electrophysiological features (electrical remodeling) can occur, resulting in a loss of sensibility to most...

  • Development of analytical methods for hydrochloride salts of cardiocyclide, a new Russian class III antiarrhythmic. Grushevskaya, L.; Pyatin, B.; Stepanenko, O.; Avdyunina, N.; Lezina, V.; Prokof’eva, V. // Pharmaceutical Chemistry Journal;Aug2007, Vol. 41 Issue 8, p440 

    Cardiocyclide, a new Russian class III antiarrhythmic agent, was developed at the State V. V. Zakusov Science Research Institute Pharmacology, Russian Academy of Medical Sciences. The aims of the present work were to study the physicochemical properties of the hydrochloride salt of this agent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics